Profile
Jessica Jensen is currently the Executive Vice President-Clinical Development at POINT Biopharma, Inc. in the United States.
Prior to this, she was the Senior Vice President-Clinical Development at Progenics Pharmaceuticals, Inc. from 2018 to 2020.
She will also be the Executive Vice President-Clinical Development at POINT Biopharma Global, Inc. from 2021 to 2023.
Ms. Jensen has a graduate degree from George Washington University and an undergraduate degree from St. Joseph's University.
Jessica Jensen active positions
| Companies | Position | Start |
|---|---|---|
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Develops next-generation radioligand therapies for the treatment of cancer | Chief Tech/Sci/R&D Officer | 01/08/2020 |
Former positions of Jessica Jensen
| Companies | Position | End |
|---|---|---|
| POIT BIOP | Chief Tech/Sci/R&D Officer | 27/12/2023 |
| PROGENICS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/08/2020 |
Training of Jessica Jensen
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Progenics Pharmaceuticals, Inc.
Progenics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets medicines for prostate cancer | Health Technology |
George Washington University
George Washington University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
St. Joseph's University
St. Joseph's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
POINT Biopharma Global, Inc.
POINT Biopharma Global, Inc. BiotechnologyHealth Technology Develops radioligand therapies for the treatment of cancer | Health Technology |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Develops next-generation radioligand therapies for the treatment of cancer | Commercial Services |
- Stock Market
- Insiders
- Jessica Jensen
















